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Abstract
Objective: Percutaneous transhepatic biliary intervention (PTBI) plays an important role in the management of biliary
obstruction, and this may be complicated by acute pancreatitis. The aim of this study was to assess the incidence of acute
pancreatitis following PTBI. Patients and methods: Patients who underwent PTBI between January 1992 and December
2003 in a tertiary referral centre were identified from the hospital database. Patients who did not have their amylase
measured post-procedure were excluded, as acute pancreatitis might have been missed. Acute pancreatitis was defined as
hyperamylasaemia of three times or more above normal in association with abdominal pain. Results: Over a 12-year period,
331 patients underwent 613 procedures. Serum amylase was measured after 134 procedures (21.9%) and was elevated in 26
of those (19.4%). There was no difference in the frequency of hyperamylasaemia between proximal and distal PTBI (14/73
[19.2%] vs 12/61 [19.7%] procedures, p/NS). However, acute pancreatitis developed after 4 of 61 (6.6%) distal PTBI
(stent, n/3; internalexternal catheter insertion, n/1) but not after proximal PTBI (cholangiography or external
drainage) (p/0.041). The attacks were mild in three of the four patients. No pancreatitis-related deaths occurred.
Conclusion: The risk of acute pancreatitis after distal PTBI is under-recognized and should be considered as a consent issue
in patients scheduled for distal PTBI and when post-procedure abdominal pain ensues.
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Introduction
The percutaneous transhepatic approach to the biliary
tree plays an important role in the management of
biliary obstruction. Percutaneous transhepatic cho-
langiography (PTC) is preferred over endoscopic
retrograde cholangiography (ERCP) in patients with
hilar biliary obstruction. Disease unresectability and
failure of the endoscopic route are common indica-
tions for percutaneous insertion of a biliary stent [1].
In addition, the transhepatic route may be employed
to obtain a biopsy from a biliary stricture and to
retrieve calculi after failure of the endoscopic ap-
proach [2,3]. Albeit safe in experienced hands, recent
series indicate that percutaneous drainage or stent
insertion carries a small risk of severe bleeding (0.5
4.1%) [46], bile leak (0.51.6%) [2,7] and subse-
quent sepsis (0.51.9%) [5,8], with an overall rate of
major complications of 310% and procedure-related
mortality of 0.10.8% [2,5]. These risks are compar-
able to those of the endoscopic approach, which has a
complication rate of 3.614% and a mortality rate of
0.5% [5].
Rarely, acute pancreatitis might complicate PTBI
[1,9,10]. The aim of this retrospective study was to
investigate the incidence of acute pancreatitis follow-
ing PTBI and to relate the risk of acute pancreatitis to
the type of biliary intervention. The patients who
developed post-procedure acute pancreatitis are pre-
sented, and the clinical relevance of this entity is
discussed.
Materials and methods
Patients and data collection
The database of the Department of Radiology was
searched retrospectively for patients who had under-
gone PTC and associated intervention during a 12-
year period between January 1992 and December
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2003. The search retrieved all patients’ names listed
under the following departmental codes for percuta-
neous transhepatic cholangiography, drainage and
biliary stenting. The database of the Department of
Medical Records was also searched for the procedure
code for PTC during the same period and the names
retrieved were cross-referenced with those obtained
from the database of the Department of Radiology.
For all patients identified a search of the biochemistry
database was conducted for serum amylase levels
measured within 48 h of the procedure. The results
and the normal ranges at the times of measurement
were recorded. The clinical notes of patients with
hyperamylasaemia were retrieved and the clinical
details of patients who fulfilled the definition of acute
pancreatitis were reviewed and are herein presented.
Definitions
Acute pancreatitis was defined as hyperamylasaemia
of three times or more above normal in association
with abdominal pain [11,12]. The incidence of
pancreatitis was calculated only for patients who had
their serum amylase measured post-procedure. Pa-
tients who did not have their amylase measured were
excluded from the study, as acute pancreatitis could
not be ruled out with certainty. It is worth noting that
abdominal pain following PTC is not uncommon and
that even a severe attack of acute pancreatitis com-
plicating PTBI may escape clinical recognition [8]
unless serum amylase is measured or cross-sectional
imaging is performed.
Attacks were classified as ‘mild’ or ‘severe’ accord-
ing to the criteria recommended by the 1992 Atlanta
International Symposium, based on clinical outcome
[13]. Mild attacks were defined as those associated
with minimal organ dysfunction and uneventful
recovery, while severe attacks were associated with
organ failure and/or the development of local compli-
cations such as pancreatic necrosis, abscess or pseu-
docyst.
Distal biliary manipulation (distal PTBI) was
defined as the insertion of a plastic or self-expanding
metal stent (SEMS) or the placement of an internal
external drainage catheter, while proximal PTBI
described patients who underwent percutaneous cho-
langiography and/or external drainage only.
Statistical analysis
Data were analysed using the software package SPSS
10 (Chicago, IL, USA). Categorical data were com-
pared using the x2 test, and significance was accepted
at the 0.05 level.
Results
Patients and procedures
Some 331 patients (171 male, 51.7%) with a median
age of 64 years (range 24102) underwent 613
PTBI over a 12-year period of this retrospective study.
The median number of PTBI procedures per patient
was two (range/17 procedures), and 170 patients
(51%) had more than one procedure. The interven-
tions performed involved manipulation of the
distal bile duct in 233 of the 613 procedures (38%)
(Table I).
Hyperamylasaemia and acute pancreatitis
Serum amylase was measured after 134 of the 613
procedures (21.9%) within 48 h. Hyperamylasaemia
was reported after 26 of the 134 procedures (19.4%),
and was greater than three times the normal range
after 10 procedures (Table I). All the patients who
developed hyperamylasaemia following ERCP or
other endoscopic procedures were excluded from
this study.
There was no significant difference in the frequency
of hyperamylasaemia between patients with proximal
and distal biliary intervention (19.2% vs 19.7%).
However, acute pancreatitis developed after 4 of 61
procedures (6.5%) that involved distal bile duct
manipulation (stent insertion, n/3; internalexternal
drainage, n/1) but did not occur when no manipula-
tion had taken place (p/0.041). The incidence of
post-PTBI acute pancreatitis (Table I) among patients
who had their serum amylase measured post-proce-
dure was 2.9% (4 of 134 procedures) and among
those who had distal biliary intervention alone was
6.6% (4 of 61 procedures).
Table I. Type of percutaneous transhepatic biliary intervention.
Post-procedure amylase
Type of intervention
No. (%) of
procedures No. measured No. (%) elevated
No. (%)
3/ elevated
No. (%) with acute
pancreatitis
Cholangiography alone 115 (18.8) 17 6/134 (4.5) 2/134 (1.5) 0
External biliary drainage 265 (43.2) 56 8/134 (6) 3/134 (2.2) 0
Internalexternal biliary drainage 64 (10.4) 13 2/134 (1.5) 1/134 (0.7) 1/134 (0.7)
Biliary stent insertion 169 (27.6) 48 10/134 (7.5) 4/134 (2.9) 3/134 (2.2)
Total 613 134 26/134 (19.4) 10/134 (7.5) 4/134 (2.9)
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The details of the four patients who developed post-
procedure acute pancreatitis are listed in Table II. The
attacks of acute pancreatitis were mild in three
patients and severe in one who developed acute renal
impairment and fulfilled the Atlanta criteria for
definition of severity of acute pancreatitis [13] (serum
creatinine 213 umol/l, normal B/110 umol/l),
although he recovered rapidly. Acute pancreatitis
was recognized in three patients and was missed in
one with a mild attack in whom the result of serum
amylase was overlooked and the abdominal pain was
attributed to post-procedural pain. All four patients
received conservative treatment on the ward and did
not require intensive therapy support or admission to
a high dependency unit. There were no pancreatitis-
related deaths. However, one patient with pancreatic
cancer died 30 days after the PTBI as a result of
disease progression.
Discussion
Retrograde manipulation of the ampulla, distal bile
duct or pancreatic duct, whether performed endosco-
pically or operatively (e.g. sphincteroplasty of the
sphincter of Oddi) carries a well-recognized risk of
acute pancreatitis [14,15]. Similarly, antegrade ma-
nipulation of the distal bile duct such as at the time of
exploration of the common bile duct and instrumental
retrieval of distal biliary calculi is associated with a risk
of acute pancreatitis [16]. Acute pancreatitis compli-
cating PTBI has been documented in 11 patients in
the literature [1,8,10,17,18] and in 5 patients in this
report.
The diagnosis of acute pancreatitis is, by and large,
based on hyperamylasaemia of three times or more
above normal in association with abdominal pain
[11,12]. Hyperamylasaemia per se, however, is not
uncommon after percutaneous or endoscopic biliary
intervention, occurring in 11.312.8% of patients
undergoing ERCP [19,20]. We have observed hyper-
amylasaemia without clinical features of acute
pancreatitis in 1:6 patients who underwent PTC
with or without concomitant biliary interventions in
whom post-procedure serum amylase was measured.
Savader et al. reported hyperamylasaemia in 24% of
patients who underwent similar percutaneous proce-
dures [21]. However, the incidence of acute pancrea-
titis in our study was 6.5% after distal PTBI and
3.7% when all percutaneous transhepatic/diagnostic
procedures were considered.
We acknowledge the limitation of this retrospective
study in determining the exact incidence of acute
pancreatitis following PTBI, as serum amylase was
measured in only one-fifth of patients post-procedure.
Although it is likely that the exclusion of patients who
did not have their serum amylase measured post-
procedure might have biased the results towards a
higher than the true incidence of acute pancreatitis (as
presumably these patients did not have prolonged or
undue abdominal pain and therefore it is highly likely
that they did not have acute pancreatitis), one cannot
reliably rule out this complication on the basis of
symptoms alone. Indeed, acute pancreatitis in one of
our four patients was not recognized by the clinicians
at the time, as the amylase result was overlooked and
the abdominal pain was attributed to post-procedure
pain. Becker and colleagues also reported acute
pancreatitis at post-mortem examination in a patient
who underwent percutaneous transhepatic biliary
stent insertion in whom the diagnosis was not made
clinically [8]. Although Savader et al. [21] reported an
incidence of post-PTBI acute pancreatitis of 10% (5
of 50 patients), 3 of the patients in that series did not
fulfil the definition criteria, as the rise in amylase was
Table II. Clinical details of patients with post-intervention acute pancreatitis.
No.
Age
(sex) Diagnosis
Previous
procedures
Percutaneous
biliary
intervention
associated with
acute pancreatitis
Severity of
acute
pancreatitis
Serum
amylase:
pre-/post-
procedure
(U/L) Complications
Post-procedure
hospital stay
(days)
1 51 (M) Hilar
cholangiocarcinoma
PTC (n/1),
EBD (n/2)
12 Fr plastic
stent inserted
Mild 72/2275 None 5
2 70 (M) Pancreatic cancer Failed
ERCP (n/1),
EBD (n/1)
10 Fr plastic
stent and biopsy
of stricture
Severe 101/2266 Acute renal
impairment
7
3 34 (M) Lymphoma with
hilar obstruction
ERCP (n/1),
EBD (n/1)
10 Fr plastic
stent and biopsy
of stricture
Mild NA/3884 None 7
4 51 (F) Benign
anastomotic
stricture at
side-to-side
hepatico-jejunostomy
None 7 Fr internal
external drain
Mild 99/2234 Right pleural
effusion
29 (underwent
a re-do
hepatico-
jejunostomy)
PTC, percutaneous transhepatic cholangiography; EBD, external biliary drainage; ERCP, endoscopic retrograde cholangiopancreato-
graphy; NA, not available.
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less than threefold; exclusion of these patients reduces
the incidence of this complication to 4%, which is
comparable to our finding (3.7%). It is interesting to
observe that the risk of acute pancreatitis following
PTBI appears similar to that reported after a diag-
nostic (0.095%) or therapeutic (0.410%) ERCP
[14,15].
The risk of acute pancreatitis appears to be
particularly related to distal biliary manipulation
(distal PTBI) rather than percutaneous intrahepatic
or proximal biliary intervention (proximal PTBI). In
this report, acute pancreatitis developed only in
patients who underwent insertion of either a stent or
an internal-external biliary drainage catheter across
the ampulla and in none of the patients who had a
more proximal biliary intervention. Indeed, all pre-
viously reported patients with post-PTBI acute pan-
creatitis had undergone insertion of a biliary stent
[1,8,10,17,18].
The rate of immediate complications from PTBI
appears to be similar whether self-expandable metal
stents or plastic stents are inserted [8]. There is no
evidence to implicate larger size stents in post-PTBI
acute pancreatitis. Stents placed in our patients
ranged from 7 Fr to 25 Fr (8 mm). In a previous
report, Kadakia and Starnes [17] found no difference
in the rate of complications between 10 Fr and 11.5
Fr stents introduced percutaneously. Acute pancrea-
titis may occur after percutaneous placement of semi-
rigid plastic stents as well as self-expanding metal
stents, which have a smaller, more flexible delivery
system but a larger diameter (up to 10 mm) once
deployed [10]. One of three patients in this report
who developed acute pancreatitis following percuta-
neous transhepatic biliary stent insertion had received
a metal stent.
It is likely that acute pancreatitis complicating
PTBI may, in some patients, be related to haemobilia,
as some authors have previously reported [2224].
Acute pancreatitis has been reported following percu-
taneous liver biopsy [2225] and post-transhepatic
biliary drainage [1,2,9,21]. In addition, transhepatic
biopsies of bile duct lesions [3] have been complicated
with acute pancreatitis. The transhepatic biopsies of
distal bile duct strictures that were obtained at the
time of biliary stent insertion in two of our patients
might have contributed to the development of acute
pancreatitis, neither of whom developed overt signs of
gastrointestinal bleeding. Van Steenbergen et al. [10]
attributed the development of acute pancreatitis to
placement of a catheter or stent across the ampulla
with possible disruption of the function of the
sphincter of Oddi and reflux of duodenal content
into the pancreatic duct.
This report highlights the potential risk of develop-
ment of acute pancreatitis following distal PTBI with
manipulation of the ampulla, a risk that appears
similar to that seen after ERCP. Therefore it is
essential for clinicians to inform patients of this risk
when obtaining a consent for PTBI, and to be alert to
the development of acute pancreatitis should severe
abdominal pain ensue post-intervention, to provide
timely diagnosis and management.
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